804 related articles for article (PubMed ID: 32004713)
1. IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Travis WD; Dacic S; Wistuba I; Sholl L; Adusumilli P; Bubendorf L; Bunn P; Cascone T; Chaft J; Chen G; Chou TY; Cooper W; Erasmus JJ; Ferreira CG; Goo JM; Heymach J; Hirsch FR; Horinouchi H; Kerr K; Kris M; Jain D; Kim YT; Lopez-Rios F; Lu S; Mitsudomi T; Moreira A; Motoi N; Nicholson AG; Oliveira R; Papotti M; Pastorino U; Paz-Ares L; Pelosi G; Poleri C; Provencio M; Roden AC; Scagliotti G; Swisher SG; Thunnissen E; Tsao MS; Vansteenkiste J; Weder W; Yatabe Y
J Thorac Oncol; 2020 May; 15(5):709-740. PubMed ID: 32004713
[TBL] [Abstract][Full Text] [Related]
2. International Association for the Study of Lung Cancer Study of Reproducibility in Assessment of Pathologic Response in Resected Lung Cancers After Neoadjuvant Therapy.
Dacic S; Travis W; Redman M; Saqi A; Cooper WA; Borczuk A; Chung JH; Glass C; Lopez JM; Roden AC; Sholl L; Weissferdt A; Posadas J; Walker A; Zhu H; Wijeratne MT; Connolly C; Wynes M; Bota-Rabassedas N; Sanchez-Espiridion B; Lee JJ; Berezowska S; Chou TY; Kerr K; Nicholson A; Poleri C; Schalper KA; Tsao MS; Carbone DP; Ready N; Cascone T; Heymach J; Sepesi B; Shu C; Rizvi N; Sonett J; Altorki N; Provencio M; Bunn PA; Kris MG; Belani CP; Kelly K; Wistuba I;
J Thorac Oncol; 2023 Oct; 18(10):1290-1302. PubMed ID: 37702631
[TBL] [Abstract][Full Text] [Related]
3. Pathologic Response Evaluation in Neoadjuvant-Treated Lung Cancer.
Dacic S
Surg Pathol Clin; 2024 Jun; 17(2):287-293. PubMed ID: 38692811
[TBL] [Abstract][Full Text] [Related]
4. Controversies and challenges in the pathologic examination of lung resection specimens after neoadjuvant treatment.
Weissferdt A; Pataer A; Swisher SG; Heymach JV; Gibbons DL; Cascone T; Sepesi B
Lung Cancer; 2021 Apr; 154():76-83. PubMed ID: 33631448
[TBL] [Abstract][Full Text] [Related]
5. Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.
Weissferdt A; Leung CH; Lin H; Sepesi B; William WN; Swisher SG; Cascone T; Lee JJ; Pataer A
Mod Pathol; 2024 Jan; 37(1):100353. PubMed ID: 37844869
[TBL] [Abstract][Full Text] [Related]
6. Pathological assessment of resection specimens after neoadjuvant therapy for metastatic melanoma.
Tetzlaff MT; Messina JL; Stein JE; Xu X; Amaria RN; Blank CU; van de Wiel BA; Ferguson PM; Rawson RV; Ross MI; Spillane AJ; Gershenwald JE; Saw RPM; van Akkooi ACJ; van Houdt WJ; Mitchell TC; Menzies AM; Long GV; Wargo JA; Davies MA; Prieto VG; Taube JM; Scolyer RA
Ann Oncol; 2018 Aug; 29(8):1861-1868. PubMed ID: 29945191
[TBL] [Abstract][Full Text] [Related]
7. Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group.
Provenzano E; Bossuyt V; Viale G; Cameron D; Badve S; Denkert C; MacGrogan G; Penault-Llorca F; Boughey J; Curigliano G; Dixon JM; Esserman L; Fastner G; Kuehn T; Peintinger F; von Minckwitz G; White J; Yang W; Symmans WF;
Mod Pathol; 2015 Sep; 28(9):1185-201. PubMed ID: 26205180
[TBL] [Abstract][Full Text] [Related]
8. Two commonly used neoadjuvant chemoradiotherapy regimens for locally advanced stage III non-small cell lung carcinoma: long-term results and associations with pathologic response.
Machtay M; Lee JH; Stevenson JP; Shrager JB; Algazy KM; Treat J; Kaiser LR
J Thorac Cardiovasc Surg; 2004 Jan; 127(1):108-13. PubMed ID: 14752420
[TBL] [Abstract][Full Text] [Related]
9. Pathologic features of response to neoadjuvant anti-PD-1 in resected non-small-cell lung carcinoma: a proposal for quantitative immune-related pathologic response criteria (irPRC).
Cottrell TR; Thompson ED; Forde PM; Stein JE; Duffield AS; Anagnostou V; Rekhtman N; Anders RA; Cuda JD; Illei PB; Gabrielson E; Askin FB; Niknafs N; Smith KN; Velez MJ; Sauter JL; Isbell JM; Jones DR; Battafarano RJ; Yang SC; Danilova L; Wolchok JD; Topalian SL; Velculescu VE; Pardoll DM; Brahmer JR; Hellmann MD; Chaft JE; Cimino-Mathews A; Taube JM
Ann Oncol; 2018 Aug; 29(8):1853-1860. PubMed ID: 29982279
[TBL] [Abstract][Full Text] [Related]
10. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
11. [Histopathological features of squamous cell carcinoma of lung neoadjuvant immunotherapy focusing on responses].
Wei JC; Yuan P; Ling Y; Li L; Guo CY; Guo L; Xue LY; Ying JM
Zhonghua Bing Li Xue Za Zhi; 2021 May; 50(5):453-457. PubMed ID: 33915650
[No Abstract] [Full Text] [Related]
12. Pathologic changes in breast cancer following neoadjuvant chemotherapy: implications for the assessment of response.
Rajan R; Esteva FJ; Symmans WF
Clin Breast Cancer; 2004 Aug; 5(3):235-8. PubMed ID: 15335458
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant and Neoadjuvant Immunotherapy in Non-small Cell Lung Cancer.
Broderick SR
Thorac Surg Clin; 2020 May; 30(2):215-220. PubMed ID: 32327180
[TBL] [Abstract][Full Text] [Related]
14. New Developments in Neoadjuvant Therapy for Lung Cancer.
Bunn PA; Schenk E; Pacheco J; Dimou A
Oncology (Williston Park); 2019 Mar; 33(3):101-6, 109. PubMed ID: 30866032
[TBL] [Abstract][Full Text] [Related]
15. Relationship of clinical and pathologic response to neoadjuvant chemotherapy and outcome of locally advanced breast cancer.
Gajdos C; Tartter PI; Estabrook A; Gistrak MA; Jaffer S; Bleiweiss IJ
J Surg Oncol; 2002 May; 80(1):4-11. PubMed ID: 11967899
[TBL] [Abstract][Full Text] [Related]
16. Pathologic Assessment After Neoadjuvant Chemotherapy for NSCLC: Importance and Implications of Distinguishing Adenocarcinoma From Squamous Cell Carcinoma.
Qu Y; Emoto K; Eguchi T; Aly RG; Zheng H; Chaft JE; Tan KS; Jones DR; Kris MG; Adusumilli PS; Travis WD
J Thorac Oncol; 2019 Mar; 14(3):482-493. PubMed ID: 30503889
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant chemoradiotherapy followed by surgery for stage IIIa and IIIb non-small-cell lung cancer (NSCLC): is it still justified?
Mirimanoff RO
Chin Clin Oncol; 2015 Dec; 4(4):49. PubMed ID: 26730761
[TBL] [Abstract][Full Text] [Related]
18. The new IASLC/ATS/ERS lung adenocarcinoma classification from a clinical perspective: current concepts and future prospects.
Zugazagoitia J; Enguita AB; Nuñez JA; Iglesias L; Ponce S
J Thorac Dis; 2014 Oct; 6(Suppl 5):S526-36. PubMed ID: 25349703
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant chemotherapy followed by surgery in lung cancer: Indian scenario.
Kumar S; Saikia J; Kumar V; Malik PS; Madan K; Jain D; Bharati S
Curr Probl Cancer; 2020 Jun; 44(3):100563. PubMed ID: 32265058
[TBL] [Abstract][Full Text] [Related]
20. Histologic assessment of non-small cell lung carcinoma after neoadjuvant therapy.
Liu-Jarin X; Stoopler MB; Raftopoulos H; Ginsburg M; Gorenstein L; Borczuk AC
Mod Pathol; 2003 Nov; 16(11):1102-8. PubMed ID: 14614049
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
